Kallio, Heini M. L. http://orcid.org/0000-0003-4345-1787
Hieta, Reija
Latonen, Leena
Brofeldt, Anniina
Annala, Matti
Kivinummi, Kati
Tammela, Teuvo L.
Nykter, Matti
Isaacs, William B.
Lilja, Hans G.
Bova, G. Steven
Visakorpi, Tapio
Article History
Received: 14 February 2018
Revised: 8 June 2018
Accepted: 13 June 2018
First Online: 10 July 2018
Competing interests
: The authors declare no competing interests.
: The use of benign prostatic hyperplasia, hormone-naïve prostate cancer and locally recurrent CRPC specimens was approved by the ethical committee of the Tampere University Hospital. Written informed consent was obtained from the subjects. Samples from non-androgen deprived pelvic lymph node metastases were obtained under Johns Hopkins Medicine IRB approval 04-05-03-02. Metastatic CRPC specimens were obtained from 30 men who participated in the PELICAN (Project to ELIminate lethal CANcer) integrated clinical-molecular autopsy study of metastatic prostate cancer. Subjects consented to participate in the Johns Hopkins Medicine IRB-approved study between 1995 and 2005. The study was performed in accordance with the Declaration of Helsinki.
: All data generated or analysed during this study are included in this published article [and its supplementary information files].
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).